An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic
- 17 Feb 2014 New trial record